Detalles de la búsqueda
1.
Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis.
Diabetes Obes Metab
; 25(6): 1589-1606, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36748186
2.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Diabetes Obes Metab
; 25(6): 1485-1494, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36708333
3.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin® R formulation in healthy subjects: Results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study.
Diabetes Obes Metab
; 24(4): 713-721, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34981621
4.
Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US-licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study.
Diabetes Obes Metab
; 24(9): 1819-1828, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35589611
5.
Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 188(2): 369-377, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34125340
6.
Media milling process optimization for manufacture of drug nanoparticles using design of experiments (DOE).
Drug Dev Ind Pharm
; 41(1): 124-30, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24180259
7.
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung Cancer.
Eur J Drug Metab Pharmacokinet
; 48(6): 675-689, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37792130
8.
REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT.
Expert Opin Biol Ther
; 23(5): 443-454, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37073744
9.
Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study.
Expert Opin Pharmacother
; 23(16): 1855-1863, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36352762
10.
A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
Expert Opin Biol Ther
; 21(5): 675-686, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33835886
11.
Physicochemical and functional characterization of trastuzumab-dkst, a trastuzumab biosimilar.
Future Med Chem
; 13(18): 1531-1557, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34289749
12.
Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial.
Breast
; 58: 18-26, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33892316
Resultados
1 -
12
de 12
1
Próxima >
>>